Received Mar 3, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTPPVHBHPB | DTAP+IPV+HIB+HEPB (VAXELIS) | MSP VACCINE COMPANY | UNK | u7969aa | LL |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | UNK | y004552 | — |
Extra dose administered; Fever; patient received both VAXELIS and RECOMBIVAX HB at the same time last week; This spontaneous safety report, with reference number 02924078 (Interaction Number: 02924071), was received by the partner on 22-DEC-2025 and forwarded to agency on 24-DEC-2025, from a health care professional. Due to the nature of the event, the causality between the events "patient received both VAXELIS and RECOMBIVAX HB at the same time last week" and "Extra dose administered" and Vaxelis was not applicable. Further information is expected. SIGNIFICANT FOLLOW-UP INFORMATION was received through Fax on 12-JAN-2026 from a health professional. This case is maintained as non-serious. Due to the nature of the event, the causality between the events "patient received both VAXELIS and RECOMBIVAX HB at the same time last week" and "Extra dose administered" and Vaxelis was not applicable. No further information is expected.
Prophylaxis
PREVENAR 20